CEO
Steven Mento
Employees
25
Industry
Pharmaceutical Preparation Manufacturing
a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.
Loading...
Open
0.21
Mkt cap
897K
Volume
25
High
0.21
P/E Ratio
-0.07
52-wk high
0.55
Low
0.21
Div yield
N/A
52-wk low
0.05
Portfolio Pulse from Benzinga Insights
October 05, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
October 04, 2023 | 5:31 pm
Portfolio Pulse from Lisa Levin
October 04, 2023 | 4:48 pm
Portfolio Pulse from Benzinga Insights
October 03, 2023 | 9:31 pm
Portfolio Pulse from Lisa Levin
September 20, 2023 | 6:10 pm
Portfolio Pulse from Benzinga Insights
September 20, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
September 20, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Insights
September 19, 2023 | 9:31 pm
Portfolio Pulse from Lisa Levin
September 19, 2023 | 6:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.